Dobianjeong (Calcium Dobesilate Hydrate)

Adult dose

Adults: Administer the following doses of calcium dobesilate orally. 1. Vascular damage and retinopathy: 500-1000 mg per day 2. Venous disease: 750mg per day for 1-3 weeks, followed by 500mg per day. Take after meals with plenty of fluids. Adjust the dose as appropriate according to age and symptoms.

This medicine should not be used in patients with hypersensitivity to this drug or its components. It contains lactose, so it should not be administered to patients with lactose intolerance, hereditary lactose enzyme deficiency, or glucose-galactose malabsorption disorder. Caution is advised when using in patients with impaired kidney function, and dosage adjustment is necessary for patients requiring dialysis due to renal failure. Caution is also advised in patients with impaired liver function, and if liver enzyme levels rise, the benefits and risks of treatment should be re-evaluated. This medication contains sodium metabisulfite, which may cause allergic reactions or asthma attacks in patients allergic to sulfites, so caution is required. While using this medication, symptoms such as headache, abdominal pain, nausea, diarrhea, vomiting, arthralgia, and myalgia may occur, and if skin rashes, fever, or changes in blood counts occur, treatment should be stopped immediately and medical consultation sought. Rarely, a serious blood disorder known as agranulocytosis may occur, so if high fever or infection symptoms appear, the physician should be informed immediately. If serious allergic reactions such as hypersensitivity or anaphylaxis occur, use of the medication should be stopped immediately, and emergency treatment should be sought. Experience with this medication during pregnancy is limited, so it is best to avoid use if possible, and during breastfeeding, this medication can be secreted in small amounts into breast milk, potentially affecting the infant, so treatment should be discontinued or breastfeeding should be stopped. Safety and effectiveness in pediatric patients have not been sufficiently studied, so use in children should be cautious. The effects of this medication on driving or operating machinery are not clear, so caution is necessary. While being treated, this medication may affect blood test results, so the healthcare provider should be informed before tests are conducted. No specific symptoms have been reported in cases of overdose, but general emergency treatment should be administered.

• Agranulocytosis
• neutropenia
• leukopenia
• skin rash
• allergic dermatitis
• pruritus
• urticaria
• facial swelling
• anaphylactic reaction
• headache

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1°C and 30°C at room temperature. Proper storage will help maintain the drug's efficacy and prevent degradation.

Appearance

White rectangular tablet

Package unit

For oral use - 10 tablets/PTP, For oral use - 9 PTP/box [90 tablets (10 tablets/PTP x 9)]